Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes

Part of paid clinical trials in Stanford, California.

Sponsor
Stanford University
Study ID
NCT02140983
Phase
PHASE1
Status
Completed

Conditions

  • Dementia
  • Insulin Resistance

Eligibility Criteria

Sex
ALL
Age
50 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • Liraglutide — DRUG
    90 days of liraglutide up to 1.8mg/day.
  • Placebo — DRUG
    Placebo medication

Study Details

The purpose of this study is to evaluate the effects of liraglutide on the memory and attention of people with insulin resistance. Liraglutide is a medication that makes the body more sensitive to insulin, and therefore may allow it to manage sugar more effectively. The investigators are looking specifically at a region of the brain that is associated with memory and attention, called the hippocampus, in order to see whether treatment this treatment will change performance on memory and attention tasks. The investigators are also taking an MRI of the brain to see whether there are changes to the size and shape of the hippocampus after treatment. All subjects in this study will be 50-70 years old and have pre- diabetes. Half of all subjects will have a family history of dementia, while the other half will not.

Key Dates

Start date
Aug 31, 2013
Status verified
Jan 2018
Primary completion
Feb 28, 2017
Completion
Feb 28, 2017

Study Design

Enrollment
41 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Liraglutide
    90 days of liraglutide treatment at adjusting dose, up to 1.8mg/day
  • Placebo Comparator: Placebo
    90 days of placebo pen, up to 1.8mg/day.

Primary Outcome Measure

Cognitive Outcomes [ Time Frame: Change from Baseline to 3 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford Department of PsychiatryStanfordCalifornia94305-

Find similar trials in Stanford, CA

Related Studies